View |
BR-1474_PI_01.pdf
|
BR-1474
|
Semaglutide
|
Wegovy
|
1.7 mg/0.75 mL (2.27 mg/mL)
|
Solution for Injection (SC)
|
Glucagon-like peptide (GLP-1) Analogues
|
Novo Nordisk A/S
|
Denmark
|
Monitored Release (MR)
|
22 May 2024
|
22 May 2029
|
View |
BR-1475_PI_01.pdf
|
BR-1475
|
Semaglutide
|
Wegovy
|
1 mg/0.5 mL (2 mg/mL)
|
Solution for Injection (SC)
|
Glucagon-like peptide (GLP-1) Analogues
|
Catalent Belgium
|
Belgium
|
Monitored Release (MR)
|
22 May 2024
|
22 May 2029
|
View |
BR-1476_PI_01.pdf
|
BR-1476
|
Semaglutide
|
Wegovy
|
0.5 mg/0.5 mL (1 mg/mL)
|
Solution for Injection (SC)
|
Glucagon-like peptide (GLP-1) Analogues
|
Catalent Belgium
|
Belgium
|
Monitored Release (MR)
|
22 May 2024
|
22 May 2029
|
View |
BR-1477_PI_01.pdf
|
BR-1477
|
Semaglutide
|
Wegovy
|
0.25 mg/0.5 mL (0.5 mg/mL)
|
Solution for
Injection (SC)
|
Glucagon-like peptide (GLP-1) Analogues
|
Catalent Belgium
|
Belgium
|
Monitored Release (MR)
|
22 May 2024
|
22 May 2029
|
View |
|
BR-1478
|
Rituximab
|
Rituxell
|
10 mg/mL
|
Concentrate for Solution for Infusion (IV)
|
Monoclonal Antibodies
|
Joint Stock Company Biocad
|
Russia
|
Initial
|
28 February 2024
|
28 February 2029
|
View |
|
BR-1479
|
Bevacizumab
|
Bevalast
|
25 mg/mL
|
Concentrate for Solution for Infusion (IV)
|
Monoclonal Antibodies
|
Joint Stock Company Biocad
|
Russia
|
Initial
|
28 February 2024
|
28 February 2029
|
View |
|
BR-1480
|
Spesolimab
|
Spevigo
|
450 mg/7.5 mL (60 mg/mL)
|
Concentrate for Solution for
Infusion (IV)
|
Interleukin inhibitors
|
Boehringer Ingelheim Pharma GmbH & Co. KG
|
Germany
|
Monitored Release (MR)
|
05 April 2024
|
05 April 2029
|
View |
|
BR-1481
|
Heparin Sodium
|
Hepadur
|
1000 IU/mL
|
Solution for Injection (IV)
|
Antithrombotic agents
|
Tianjin Biochemical Pharmaceutical Co., Ltd
|
China
|
Renewal
|
05 May 2024
|
19 May 2029
|
View |
|
BR-1482
|
Heparin Sodium
|
Hepadur
|
5000 IU/mL
|
Solution for Injection (IV)
|
Antithrombotic agents
|
Tianjin Biochemical Pharmaceutical Co., Ltd
|
China
|
Renewal
|
27 May 2024
|
19 May 2029
|
View |
|
BR-1483
|
Meningococcal group B Vaccine (rDNA, component,
adsorbed)
|
Bexsero
|
Formulation:
One dose (0.5 mL) contains:
Recombinant Neisseria meningitidis group B NHBA fusion protein1.2.3 -50 mcg Recombinant Neisseria meningitidis-group B NadA protein1.2.3- 50 mcg
Recombinant Neisseria meningitidis group B fHbp fusion protein1.2.3 -50 mcg
Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain 25 mcg
NZ98/254 measured as amount of total protein containing the PorA P1.42
produced in E. coli cells by recombinant DNA technology
2Adsorbed on Aluminum hydroxide (0.5 mg Al1)
'NHBA (Neisseria Heparin Binding Antigen), NadA (Neisseria adhesin A). (Hbp
(factor H binding protein)
|
Suspension for Injection (IM)
|
Meningococcal Vaccines
|
GlaxoSmithKline Vaccines S.r.1
|
Italy
|
Monitored Release (MR)
|
21 May 2024
|
21 May 2029
|
View |
|
BR-1484
|
Eptacog alfa (activated)
|
NovoSeven RT
|
1 mg
|
Powder for Solution for Injection (IV)
|
Blood Coagulation Factor
|
Novo Nordisk A/S
|
Denmark
|
Initial (Reapplication)
|
01 July 2024
|
01 July 2029
|
View |
|
BR-1485
|
Luspatercept
|
Rojusna
|
75 mg
|
Powder for Solution for Injection (SC)
|
Antianemic Preparations
|
Patheon Italia S.p.A.
|
Italy
|
Monitored Release (MR)
|
30 July 2024
|
30 July 2029
|
View |
|
BR-1486
|
Luspatercept
|
Rojusna
|
25 mg
|
Powder for Solution for Injection (SC)
|
Antianemic Preparations
|
Patheon Italia S.p.A.
|
Italy
|
Monitored Release (MR)
|
30 July 2024
|
30 July 2029
|
View |
|
BR-220
|
Rabbies Vaccine (Inactivated)(Wistar Strain Rabies)
|
Verorab
|
2.5 IU/ 0.5 mL
|
Powder For Suspension(ID/IM)
|
-
|
Sanofi Pasteur, Inc.
|
France
|
Renewal
|
26 May 2023
|
10 December 2027
|
View |
|
BR-233
|
Hepatitis B (rDNA) Vaccine
|
Engerix-B
|
20mcg/mL
|
Suspension for IM Injection (Thiomersal-free/Preservative-free)
|
Vaccine
|
GlaxoSmithKline Biologicals SA
|
Belgium
|
Renewal
|
04 June 2021
|
04 December 2024
|
View |
|
BR-254
|
Hepatitis B (rDNA) Vaccine
|
Engerix-B
|
10mcg/0.5mL
|
Suspension for IM Injection (Thiomersal-free/Preservative-free)
|
Vaccine
|
GlaxoSmithKline Biologicals SA
|
Belgium
|
Renewal
|
04 June 2021
|
04 December 2024
|
View |
|
BR-280
|
Typhoid Polysaccharide Vaccine
|
Typhim Vi
|
Formulation: Each dose (0.5 mL) contains: Purified Vi capsular polysaccharide of Salmonella typhi (Ty2 strain)...................... 25 mcg
|
Solution for Injection (IM/SC)
|
-
|
Sanofi Pasteur
|
France
|
-
|
18 March 2022
|
01 March 2027
|
View |
|
BR-289
|
Rabbit Anti-Human Thymocyte Immunoglobulin
|
Thymoglobuline
|
5 mg/mL
|
Powder for Solution for Infusion (IV)
|
-
|
Genzyme Polyclonal S.A.S.
|
France
|
Regular Renewal (Compliance)
|
30 March 2022
|
08 February 2026
|
View |
|
BR-307
|
Hepatitis B Immunoglobulin (Human)
|
Hepabig
|
200 IU/mL
|
Solution For Injection
|
Immunoglobulin
|
Green Cross Corporation
|
Korea
|
Renewal
|
07 April 2022
|
22 March 2027
|
View |
|
BR-324
|
Diphtheria-Tetanus Toxoids And Pertussis ( DTP ) Vaccines
|
Perdinus
|
30 IU (25 Lf) / 40 IU (5 Lf) / 4 IU per 0.5 mL
|
Suspension for Injection (IM) (Monodose)
|
-
|
Serum Institute of India Private Limited
|
India
|
-
|
26 February 2021
|
28 December 2025
|